Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
Status:
Recruiting
Trial end date:
2022-07-23
Target enrollment:
Participant gender:
Summary
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo
the screening evaluations to determine eligibility within 28 days prior to study drug
administration. Approximately 80 eligible patients will be randomized in a 1:1:1:1 ratio to 1
of 4 treatment groups.